Business Wire

Prometheus Slashes Cost of Carbon Capture by More Than 80%, Unlocking Affordable E-Fuels as a New Source of 24/7 Carbon Neutral Power

15.9.2025 10:00:00 CEST | Business Wire | Press Release

Share

Prometheus Fuels (Prometheus), the company producing low-cost carbon neutral fuels from direct air capture and renewable electricity, today announced it has achieved the lowest-cost carbon capture in the world, reducing the cost of Direct Air Capture (DAC) by more than 80 percent compared to industry averages. At under $50 per ton, Prometheus’ DAC cost breakthrough unlocks carbon neutral fuels at fossil fuel prices, without relying on subsidies, biogenic carbon, or point-source emissions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915079297/en/

Prometheus builds a 200-ton-per-year Direct Air Capture system at its California HQ, adding capacity to its currently operating 16-TPY system, the world’s lowest-cost DAC technology at less than $50 per ton CO₂.

The achievement is demonstrated in Prometheus’ new 200-ton-per-year DAC system, currently under construction and scheduled for completion this year. The system captures CO₂ directly from ambient air into water and feeds it into the company’s patented Faraday Reactor for immediate conversion into fuel. This streamlined approach bypasses traditional gas purification, compression, absorption and desorption, and costly infrastructure –dramatically reducing both energy use and capital requirements.

The announcement comes as policymakers, investors, and major emitters race to identify new carbon neutral power sources. With subsidy-driven approaches under pressure and most carbon capture technologies still too expensive to scale, Prometheus’ breakthrough offers a commercially ready, cost-competitive, new source of power – liquid fuels made from solar that can provide 24/7 carbon neutral electricity, propulsion, and heat anywhere in the world.

“Low-cost DAC unlocks the best solar locations, far away from point sources of CO2” said Rob McGinnis, founder and CEO of Prometheus. “By developing a new low-cost DAC technology, along with our hydrocarbon electrolysis Faraday Reactor, we’ve brought carbon capture below $50 a ton and made truly affordable e-fuels possible for the first time.”

Most DAC systems cost between $200 and $600 per ton of CO₂ captured, making it virtually impossible to produce synthetic fuels that compete with fossil fuel prices. Prometheus’ breakthrough slashes that cost by more than 80 percent, offering the first commercially viable model for scalable, carbon neutral fuel production.

Unlike conventional e-fuel approaches that rely on smokestacks or bio-derived CO₂, Prometheus’ modular, off-grid system gives it full geographic and economic flexibility. By decoupling fuel production from traditional carbon sources, Prometheus can site its systems wherever renewable electricity is cheapest, and inexpensively transport liquid fuels anywhere in the world.

“This isn’t just a scientific breakthrough, it’s a whole new business model,” added McGinnis. “When you combine ultra-low-cost DAC with modular, off-grid electrochemical fuel production, you open up access to remote, off-grid solar – the cheapest source of energy on the planet – making it available anywhere in the world as a new low-cost source of 24/7, firm, dispatchable, carbon neutral power.”

The company’s DAC costs and fuel economics were independently validated by Ramboll, a global engineering firm, in a detailed techno-economic analysis of Prometheus’ full production process.

Prometheus has operated the world’s only commercial-scale DAC prototype for more than four years. That system is actively producing e-fuels at the company’s Titan Forge Alpha pilot plant today. The new modular 200-ton system builds on this proven platform to scale production and meet growing demand from sectors including AI power, factories, green steel, aviation, shipping, and cities, where this new source of carbon neutral power can stabilize the grid by fueling peaker and baseload plants.

To see a demo of Prometheus fuel made from DAC and solar at the company’s Titan Forge Alpha pilot plant, visit: https://bit.ly/Promethean-Stang-Reveal

About Prometheus Fuels

Prometheus is the global leader in carbon neutral fuels made from direct air capture and renewable electricity to power AI data centers, factories, ships, vehicles, and aircraft. The company’s patented technology produces fuel at fossil fuel prices without subsidies, transforming energy production. Designed to run off-grid, Prometheus offers a scalable source of new power, transforming intermittent renewable energy into firm dispatchable 24/7 power, anywhere it is needed. Backed by top-tier investors including Maersk, BMW, Y Combinator, Paul Graham, Jaan Tallinn, John and Patrick Collison, Garrett Camp, and Tom Preston-Werner, Prometheus is redefining the future of energy. Learn more at prometheusfuels.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250915079297/en/

Contacts

Media Contacts:
Nickell Communications for Prometheus Fuels:
prometheus@nickellcommunications.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye